Opthea Wet AMD Data Featured at Macula Society Meeting
Opthea (ASX/NASDAQ:OPT) announced that its drug sozinibercept will be featured at the Macula Society 48th Annual Meeting, taking place February 12-15, 2025, in Charlotte Harbor, Florida. Dr. David S. Boyer will present data from the Phase 2b wet AMD trial during the Neovascular AMD I: Trials session on February 14, 2025.
The presentation will showcase findings demonstrating that sozinibercept 2 mg combination therapy achieved superior vision and anatomic outcomes compared to standard-of-care ranibizumab alone in treating wet age-related macular degeneration (wet AMD). The study also identified baseline angiographic lesion characteristics that were predictive of treatment response.
Opthea (ASX/NASDAQ:OPT) ha annunciato che il suo farmaco sozinibercept sarà presentato al 48° Congresso Annuale della Macula Society, che si terrà dal 12 al 15 febbraio 2025 a Charlotte Harbor, Florida. Il Dr. David S. Boyer presenterà i dati della sperimentazione di Fase 2b per la degenerazione maculare umida legata all'età (wet AMD) durante la sessione Neovascular AMD I: Trials il 14 febbraio 2025.
La presentazione mostrerà i risultati che dimostrano che la terapia combinata di sozinibercept 2 mg ha ottenuto risultati visivi e anatomici superiori rispetto al trattamento standard con ranibizumab da solo nel trattamento della degenerazione maculare umida legata all'età (wet AMD). Lo studio ha anche identificato le caratteristiche delle lesioni angioografiche di base che erano predictive della risposta al trattamento.
Opthea (ASX/NASDAQ:OPT) anunció que su medicamento sozinibercept será presentado en la 48ª Reunión Anual de la Sociedad de la Mácula, que se llevará a cabo del 12 al 15 de febrero de 2025 en Charlotte Harbor, Florida. El Dr. David S. Boyer presentará datos del ensayo de Fase 2b para la degeneración macular húmeda relacionada con la edad (wet AMD) durante la sesión Neovascular AMD I: Trials el 14 de febrero de 2025.
La presentación mostrará hallazgos que demuestran que la terapia combinada de sozinibercept 2 mg logró resultados visuales y anatómicos superiores en comparación con el tratamiento estándar con ranibizumab solo en el tratamiento de la degeneración macular húmeda relacionada con la edad (wet AMD). El estudio también identificó características de las lesiones angiográficas basales que eran predictivas de la respuesta al tratamiento.
Opthea (ASX/NASDAQ:OPT)는 자사의 약물 sozinibercept가 2025년 2월 12일부터 15일까지 플로리다의 샬럿 하버에서 열리는 48회 마큘라 학회 연례 회의에서 소개될 것이라고 발표했습니다. David S. Boyer 박사는 2025년 2월 14일 Neovascular AMD I: Trials 세션에서 습성 노인성 황반변성(wet AMD)에 대한 2b상 시험 데이터를 발표할 예정입니다.
발표에서는 sozinibercept 2 mg 복합 요법이 습성 노인성 황반변성(wet AMD) 치료에 있어 표준 치료인 ranibizumab 단독 치료에 비해 우수한 시각적 및 해부학적 결과를 달성했음을 보여주는 결과가 있습니다. 이 연구에서는 또한 치료 반응을 예측할 수 있는 기본 혈관 조영 특성을 제시했습니다.
Opthea (ASX/NASDAQ:OPT) a annoncé que son médicament sozinibercept sera présenté lors de la 48e Réunion Annuelle de la Macula Society, qui aura lieu du 12 au 15 février 2025 à Charlotte Harbor, en Floride. Le Dr David S. Boyer présentera des données de l'essai de Phase 2b sur la dégénérescence maculaire humide liée à l'âge (wet AMD) lors de la session Neovascular AMD I: Trials le 14 février 2025.
La présentation mettra en lumière des résultats démontrant que la thérapie combinée de sozinibercept 2 mg a obtenu des résultats visuels et anatomiques supérieurs par rapport à la ranibizumab en traitement standard pour la dégénérescence maculaire humide liée à l'âge (wet AMD). L'étude a également identifié des caractéristiques des lésions angiographiques de base qui étaient prédictives de la réponse au traitement.
Opthea (ASX/NASDAQ:OPT) gab bekannt, dass ihr Medikament sozinibercept auf dem 48. Jahreskongress der Macula Society vorgestellt wird, der vom 12. bis 15. Februar 2025 in Charlotte Harbor, Florida, stattfindet. Dr. David S. Boyer wird am 14. Februar 2025 im Rahmen der Sitzung Neovascular AMD I: Trials Daten aus der Phase 2b-Studie zur feuchten altersbedingten Makuladegeneration (wet AMD) präsentieren.
Die Präsentation wird Ergebnisse zeigen, die belegen, dass die Therapie mit sozinibercept 2 mg im Vergleich zur Standardbehandlung mit Ranibizumab allein überlegene visuelle und anatomische Ergebnisse bei der Behandlung der feuchten altersbedingten Makuladegeneration (wet AMD) erzielt hat. Die Studie identifizierte zudem grundlegende angiografische Läsionseigenschaften, die prognostisch für das Ansprechen auf die Behandlung waren.
- Phase 2b trial showed superior vision and anatomic outcomes for sozinibercept 2mg combination therapy vs. standard treatment
- Identified predictive baseline characteristics for treatment response
- None.
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases.
Details are as follows:
| Session: | Neovascular AMD I: Trials |
| Timing: | Friday, February 14, 2025, 8:00 to 8:05 AM ET |
| Presentation: | Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response |
| Presenter: | David S. Boyer, MD |
| Program: | https://www.xcdsystem.com/maculasociety/program/5G2onFx/index.cfm?pgid=397&RunRemoveSessionFilter=1 |
David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial demonstrating that superior vision and anatomic outcomes were observed with sozinibercept 2 mg combination therapy, compared with standard-of-care ranibizumab alone, with baseline angiographic lesion characteristics predictive of response.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.
Opthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD live fuller and healthier lives.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
| Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
What were the key findings of Opthea's Phase 2b wet AMD trial for sozinibercept?
When will Opthea (OPT) present its sozinibercept data at the Macula Society Meeting?
How does sozinibercept compare to ranibizumab in treating wet AMD?
What is the significance of the angiographic predictors in Opthea's sozinibercept study?
